Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

Novartis

Status and phase: Terminated; Phase 3

Conditions: Asthma

Treatments: Drug: QAW039 150 mg; Drug: Placebo; Drug: QAW039 450 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT03052517

2016-001560-11 (EudraCT Number)

CQAW039A2315

Details and patient eligibility

About

This study was a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when added to the Global Initiative for Asthma (GINA) steps 3, 4, and 5 standard-of-care (SoC) asthma therapy (GINA 2016), in patients with moderate-to- severe asthma.

The purpose of this study was to provide long-term safety data for QAW039 150 mg once daily and 450 mg once daily, compared with placebo, when added to GINA steps 3, 4, and 5 standard-of-care asthma therapy (GINA 2020) in adult and adolescent (≥12 years) patients with moderate-to-severe asthma. The study included 2 cohorts of patients:

1. Rollover patients who had completed any of the four Phase 3 pivotal efficacy studies with QAW039 (QAW039A2307, QAW039A2314, QAW039A2316, or QAW039A2317, hereafter referred to as Studies A2307, A2314, A2316, and A2317), thus providing data for a longer duration of exposure, and
2. New patients who had not previously participated in a study of QAW039, permitting an increase in the number of patients with long-term exposure to QAW039.

By including these 2 categories of patients, the total number of patients treated with QAW039 as well as the duration of exposure to QAW039 treatment was substantially increased, supporting evaluation of the safety profile of QAW039.

Full description

The study comprised 2-treatment period. Treatment Period 1 was a 52-week, double-blind treatment period in which QAW039 450 mg or 150 mg or placebo was added to standard-of-care asthma therapy according to GINA guidelines. Treatment Period 2 was an optional 104-week, single-blind treatment period in which patients received QAW039 450 mg or 150 mg or placebo added to standard-of-care asthma therapy according to GINA guidelines.

Enrollment: 2,538 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients completing a prior Phase 3 study of QAW039:

• Informed consent and assent (if applicable).
• Completion of the Treatment Period (on blinded study drug) of a prior Phase 3 study of QAW039.
• Patient is able to safely continue into the study as judged by the investigator.

Patients who have not previously participated in a study of QAW039:

• Written informed consent.
• A diagnosis of asthma,uncontrolled on GINA 3/4/5 asthma medication.
• Evidence of airway reversibility or airway hyper- reactivity.
• FEV1 of ≤85% of the predicted normal value.
• An ACQ score ≥1.5 prior to entering the study.

Exclusion criteria

Patients completing a prior phase 3 study of QAW039:

• Pregnant or nursing (lactating) women.
• Women of child-bearing potential unless they are using basic methods of contraception during dosing of study drug
• Patients who did not complete the Treatment Period on blinded study drug of the prior QAW039 study they participated in.
• Inability to comply with all study requirements.
• Patient who experienced a serious and drug-related AE in the prior QAW039 study they participated in.

Patients who have not previously participated in a study of QAW039:

• Use of other investigational drugs within 5 half-lives of study entry, or within 30 days, whichever is longer.
• Subjects who have participated in another trial of QAW039 (i.e.-the patient was randomized in another study).
• A QTcF (Fridericia) ≥450 msec (male) or ≥460 msec (female).
• History of malignancy with the exception of local basal cell carcinoma of the skin
• Pregnant or nursing (lactating) women.
• Serious co-morbidities.
• Patients on greater than 20 mg of simvastatin> 40 mg of atorvastatin, >40 mg of pravastatin, or >2 mg of pitavastatin. Statin doses less than or equal to these doses as well as other statins will be permitted during the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

2,538 participants in 3 patient groups, including a placebo group

QAW039 150mg

Experimental group

Description:

QAW039 Dose 1 once daily

Treatment:

Drug: QAW039 150 mg

QAW039 450 mg

Experimental group

Description:

QAW039 Dose 2 once daily

Treatment:

Drug: QAW039 450 mg

Placebo

Placebo Comparator group

Description:

Placebo once daily

Treatment:

Drug: Placebo